Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Lamisil DermaGel

Executive Summary

Topical gel formulation of antifungal terbinafine approved April 29. NDA 20-846 provides for treatment of tinea versicolor due to Malassezia furfur (formerly Pityrosporum ovale), tinea pedis (athlete's foot) or tinea corporis (ringworm) due to Trichophyton rubrum, Trychophyton mentagrophytes, or Epidermophyton floccosum. Lamisil DermaGel does not carry an indication for tinea cruris (jock itch), which is included in Lamisil cream labeling...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS032116

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel